Oncotarget

Reviews:

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

Ben Markman, Rodrigo Dienstmann and Josep Tabernero _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2010; 1:530-543. https://doi.org/10.18632/oncotarget.188

Metrics: PDF 6655 views  |   HTML 10438 views  |   ?  


Abstract

Received: August 24, 2010, Accepted: October 21, 2010, Published: October 22, 2010

It is well established that the PI3K pathway plays a central role in various cellular processes that can contribute to the malignant phenotype. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, agents targeting upstream receptor tyrosine kinases are best studied and have achieved greatest clinical success. Further downstream, despite efficacy in certain tumor types, the rapalogs have been somewhat disappointing in the clinic. Novel inhibitors of PI3K, Akt, and mTORC1 and 2 are now passing through early phase clinical trials. It is hoped that these agents will circumvent some of the shortcomings of the rapalogs and lead to meaningful benefits for cancer patients.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 188